Cancer vaccines in old age

Research output: Contribution to journalShort surveypeer-review

20 Scopus citations


The incidence of cancer has increased over the last decade, mainly due to an increase in the elderly population. Vaccine therapy for cancer is less toxic than chemotherapy or radiation and could be, therefore, especially effective in older, more frail cancer patients. However, it has been shown that older individuals do not respond to vaccine therapy as well as younger adults. This has been attributed to T cell unresponsiveness, a phenomenon also observed in cancer patients per se. This review summarizes the current knowledge of T cell unresponsiveness in cancer patients and elderly, the results of cancer vaccination in preclinical models and in clinical trials, and recent data of cancer vaccination at young and old age in preclinical models. Finally, experimental approaches will be proposed how to make cancer vaccines more effective at older age.

Original languageEnglish (US)
Pages (from-to)441-450
Number of pages10
JournalExperimental Gerontology
Issue number5 SPEC. ISS.
StatePublished - May 2007
Externally publishedYes


  • Aging
  • Breast cancer
  • Cancer vaccines
  • Immune system
  • Preclinical models

ASJC Scopus subject areas

  • Biochemistry
  • Aging
  • Molecular Biology
  • Genetics
  • Endocrinology
  • Cell Biology


Dive into the research topics of 'Cancer vaccines in old age'. Together they form a unique fingerprint.

Cite this